Catherine Abrial

Catherine Abrial

Auto-generated profile, based on publicly available information

Catherine Abrial

Division de la Recherche Clinique, Centre Jean PERRIN, Clermont-Ferrand, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
MBMathilde Bayet-Robert
Mathilde Bayet-Robert
FKFabrice Kwiatowski
Fabrice Kwiatowski
MLMarianne Leheurteur
Marianne Leheurteur
FGFrançoise Gachon
Françoise Gachon
EPEloïse Planchat
Eloïse Planchat
PCPhilippe Chollet
Philippe Chollet
Background. Since the improvement of chemotherapy with safe molecules is needed for better efficacy without supplementary toxicity, we investigated the feasibility and tolerability of the combinati...

16 January 2016 in Oncology
Verified
Journal Article
Closed access
PDF file
HMhakim mahammedi
hakim mahammedi
EPEloise Planchat
Eloise Planchat
MPMélanie Pouget
Mélanie Pouget
XDXavier DURANDO
Xavier DURANDO
HCHervé Curé
Hervé Curé
JEJean-Christophe Eymard
Jean-Christophe Eymard
Objectives: Favorable phase I results justified this pilot phase II study to assess the efficacy of docetaxel/curcumin in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (CRPC). Methods: Thirty patients with progressing CRPC and a rising prostate-specific antigen (PSA) received docetaxel/prednisone in standard conditions for 6 cycles in combination with per os curcumin, 6,000 mg/day (day -4 to day +2 of docetaxel). The co-primary endpoint was the overall response rate determined by PSA and target assessments. An ancillary study assessed the seric values of chromogranin A (CgA) and neuron-specific enolase (NSE). Results: Twenty-six patients received the scheduled treatment, 2 progressed and 2 died before the end of treatment. A PSA response was observed in 59% of patients (14% of PSA normalization) and achieved within the first three cycles for 88% of responders. Partial response was reached for 40% of evaluable patients. The regimen was well tolerated, and no adverse event was attributed to curcumin. Twenty patients were 100% curcumin compliant. The PSA level and objective response rate were not correlated with the serum values of CgA and NSE. Conclusion: This study produced additional data on curcumin as a treatment for cancer, with a high response rate, good tolerability and patient acceptability, justifying the interest to conduct a randomized trial.

25 November 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ETEmilie Thivat
Emilie Thivat
STSophie Thérondel
Sophie Thérondel
OLOlivier Lapirot
Olivier Lapirot
CACatherine Abrial
Catherine Abrial
XDXavier DURANDO
Xavier DURANDO
XDXavier DURANDO
Xavier DURANDO
Weight change during chemotherapy is reported to be associated with a worse prognosis in breast cancer patients, both with weight gain and weight loss. However, most studies were conducted prior to the common use of anthracycline-base chemotherapy and on North American populations with a mean BMI classified as overweight. Our study was aimed to evaluate the prognostic value of weight change during anthracycline-based chemotherapy on non metastatic breast cancer (European population) with a long term follow-up.

14 May 2014 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
JNJ. M. Nabholtz
J. M. Nabholtz
CAC. Abrial
C. Abrial
MMM. A. Mouret-Reynier
M. A. Mouret-Reynier
MDM. M. Dauplat
M. M. Dauplat
BWB. Weber
B. Weber
FPF. Penault-Llorca
F. Penault-Llorca
Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors for some of which the epithelial growth factor receptor (EGFR) pathway may play an important role. We investigated the efficacy and toxicity of an anti-EGFR antibody (panitumumab) combined with a standard neoadjuvant anthracycline–taxane-based chemotherapy in patients with operable, stage II–III, TNBC. Treatment in this multicentric neoadjuvant pilot study consisted of panitumumab (9 mg/kg) for eight cycles q.3 weeks combined with four cycles of 5-fluorouracil, epidoxorubicin and cyclophosphamide (FEC100: 500/100/500 mg/m2) q.3 weeks, followed by four cycles of docetaxel (T: 100 mg/m2) q.3 weeks. Following therapy, all patients underwent surgical resection. Pathologic complete response (pCR) in assessable patients was the main end point while clinical response, toxicity and ancillary studies were secondary end points. Paraffin-embedded and frozen tumor samples were systematically collected with the aim to identify predictive biomarkers of efficacy and resistance in order to select biologically defined subpopulations for potential further clinical development of the anti-EGFR antibody. Sixty patients were included with 47 assessable for pathologic response. The pCR rates were 46.8% [95% confidence interval (CI): 32.5% to 61.1%] and 55.3% [95% CI: 41.1% to 69.5%] according, respectively, to Chevallier and Sataloff classifications. The complete clinical response (cCR) rate was 37.5%. Conservative surgery was carried out in 87% of cases. Toxicity was manageable. The association of high EGFR and low cytokeratin 8/18 expression in tumor cells on one hand and high density of CD8+ tumor-infiltrating lymphocytes on the other hand were significantly predictive of pCR. Panitumumab in combination with FEC100 followed by docetaxel appears efficacious, with acceptable toxicity, as neoadjuvant therapy of operable TNBC. Several biomarkers could help define large subsets of patients with a high probability of pCR, suggesting a potential interest to further develop this combination in biologically defined subgroups of patients with TNBC. NCT00933517.

1 July 2015 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
QWQian Wang-Lopez
Qian Wang-Lopez
NCNassera Chalabi
Nassera Chalabi
CACatherine Abrial
Catherine Abrial
NRNina Radosevic-Robin
Nina Radosevic-Robin
XDXavier DURANDO
Xavier DURANDO
JNJean-Marc Nabholtz
Jean-Marc Nabholtz

3 November 2005 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
SASophie Amat
Sophie Amat
SASophie Catherine Abrial
Sophie Catherine Abrial
CACatherine Abrial
Catherine Abrial
FPFrédérique Penault-Llorca
Frédérique Penault-Llorca
RDRémi Delva
Rémi Delva
PCPhilippe Chollet
Philippe Chollet